UroGen Pharma Ltd.
URGN
Price:
$13.1
Market Cap:
$551.69M
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The ...[Read more]
Industry
Biotechnology
IPO Date
2017-05-04
Stock Exchange
NASDAQ
Ticker
URGN
The ROE as of September 2024 (TTM) for UroGen Pharma Ltd. (URGN) is 388.24%
According to UroGen Pharma Ltd.’s latest financial reports and current stock price. The company's current ROE is 388.24%. This represents a change of 2.39% compared to the average of 15.56% of the last 4 quarters.
UroGen Pharma Ltd. (URGN) Historical ROE (quarterly & annually)
How has URGN ROE performed in the past?
The mean historical ROE of UroGen Pharma Ltd. over the last ten years is -156.10%. The current 388.24% ROE has changed -348.72% with respect to the historical average. Over the past ten years (40 quarters), URGN's ROE was at its highest in in the March 2022 quarter at 166.29%. The ROE was at its lowest in in the December 2021 quarter at -338.19%.
Average
-156.10%
Median
-66.85%
Minimum
-1317.25%
Maximum
156.79%
UroGen Pharma Ltd. (URGN) ROE by Quarter and Year
Discovering the peaks and valleys of UroGen Pharma Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 887.85%
Maximum Annual ROE = 156.79%
Minimum Annual Increase = -109.34%
Minimum Annual ROE = -1317.25%
| Year | ROE | Change |
|---|---|---|
| 2023 | 156.79% | 27.46% |
| 2022 | 123.01% | -109.34% |
| 2021 | -1317.25% | 887.85% |
| 2020 | -133.34% | 139.16% |
| 2019 | -55.76% | -33.60% |
| 2018 | -83.98% | 187.68% |
| 2017 | -29.19% | 145.24% |
| 2016 | -11.90% | -84.73% |
| 2015 | -77.94% | -40.69% |
| 2014 | -131.40% | 8.94% |
UroGen Pharma Ltd. (URGN) Average ROE
How has URGN ROE performed in the past?
The current ROE of UroGen Pharma Ltd. (URGN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-345.82%
5-year avg
-245.31%
10-year avg
-156.10%
UroGen Pharma Ltd. (URGN) ROE vs. Peers
How is URGN’s ROE compared to its peers?
UroGen Pharma Ltd.’s ROE is greater than Eliem Therapeutics, Inc. (-47.03%), less than Inhibrx, Inc. (1.62%), greater than Merrimack Pharmaceuticals, Inc. (-35.28%), greater than Celcuity Inc. (-60.83%), greater than Enliven Therapeutics, Inc. (-29.31%), greater than Ikena Oncology, Inc. (-42.81%), greater than Xilio Therapeutics, Inc. (-176.51%), greater than Protara Therapeutics, Inc. (-55.03%), greater than Scholar Rock Holding Corporation (-114.96%), greater than Vaccitech plc (-34.77%), greater than Generation Bio Co. (-92.86%), greater than Kronos Bio, Inc. (-68.82%), greater than Erasca, Inc. (-131.94%), greater than C4 Therapeutics, Inc. (-44.60%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Ovid Therapeutics Inc. (-33.40%), greater than Connect Biopharma Holdings Limited (-3.40%), greater than PepGen Inc. (-62.74%), greater than Tyra Biosciences, Inc. (-27.13%), greater than Compass Therapeutics, Inc. (-28.67%), greater than Vigil Neuroscience, Inc. (-76.02%), greater than PureTech Health plc (-29.01%),
| Company | ROE | Market cap |
|---|---|---|
| -47.03% | $535.14M | |
| 1.62% | $245.95M | |
| -35.28% | $223.97M | |
| -60.83% | $555.82M | |
| -29.31% | $1.03B | |
| -42.81% | $80.11M | |
| -176.51% | $35.81M | |
| -55.03% | $39.61M | |
| -114.96% | $661.87M | |
| -34.77% | $192.73M | |
| -92.86% | $172.86M | |
| -68.82% | $55.48M | |
| -131.94% | $816.44M | |
| -44.60% | $442.37M | |
| -28.01% | $1.79B | |
| -33.40% | $75.23M | |
| -3.40% | $64.92M | |
| -62.74% | $301.78M | |
| -27.13% | $1.22B | |
| -28.67% | $224.27M | |
| -76.02% | $137.58M | |
| -29.01% | $464.80M |
Build a custom stock screener for UroGen Pharma Ltd. (URGN) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like UroGen Pharma Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
UroGen Pharma Ltd. (URGN) and other stocks custom spreadsheet templates
The easiest way to analyze a company like UroGen Pharma Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is UroGen Pharma Ltd.'s ROE?
How is the ROE calculated for UroGen Pharma Ltd. (URGN)?
What is the highest ROE for UroGen Pharma Ltd. (URGN)?
What is the 3-year average ROE for UroGen Pharma Ltd. (URGN)?
What is the 5-year average ROE for UroGen Pharma Ltd. (URGN)?
How does the current ROE for UroGen Pharma Ltd. (URGN) compare to its historical average?